Clinical Trial Update: Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 2 study of a humanized anti-IL-2 receptor monoclonal antibody for moderate-to-severe ulcerative colitis. The trial has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Humanized anti-IL-2 receptor monoclonal antibody

Snippet

Sponsor: Facet Biotech | Conditions: Ulcerative Colitis, Gastrointestinal Disease | Phase 2 | Status: COMPLETED